CARGO Therapeutics eyes one of 2023's largest IPOs in a dull year for listings

Kyle LaHucik

Senior Reporter

Biotech startup CARGO Therapeutics looks to land one of the biggest Nasdaq listings in a barren year for life sciences initial public offerings.

If the blood cancer cell therapy maker can garner enough investor intrigue for an IPO at its proposed midpoint price of $16 per share, then its Wall Street debut would be nearly equal in size to Apogee Therapeutics’ $300 million launch in July but below RayzeBio’s $311 million in September and Acelyrin’s $540 million in May.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

view job offer post your job now

TRENDING NOW

CARGO Therapeutics eyes one of 2023's largest IPOs in a dull year for listings

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Medical Affairs: The Critical Link Between Science, Physicians and Patients

CAR­GO Ther­a­peu­tics eyes one of 2023's largest IPOs in a dull year for list­ings

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Benchling

San Francisco, CA, USA

CARGO Therapeutics eyes one of 2023's largest IPOs in a dull year for listings